CLINICAL TRIALS PROFILE FOR ACLIDINIUM BROMIDE
✉ Email this page to a colleague
All Clinical Trials for ACLIDINIUM BROMIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00358436 ↗ | Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD) | Completed | AstraZeneca | Phase 3 | 2006-08-01 | To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment. |
| NCT00363896 ↗ | A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) | Completed | AstraZeneca | Phase 3 | 2006-07-01 | To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment. |
| NCT00435760 ↗ | Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients | Completed | AstraZeneca | Phase 3 | 2007-02-01 | This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment. |
| NCT00500318 ↗ | A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Completed | AstraZeneca | Phase 3 | 2007-07-01 | This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo. |
| NCT00626522 ↗ | Aclidinium/Formoterol Fixed Combination Dose Finding Study | Completed | AstraZeneca | Phase 2 | 2008-02-01 | The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials |
| NCT00706914 ↗ | Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Terminated | AstraZeneca | Phase 2 | 2008-06-30 | This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs. formoterol fumarate twice daily. The study will assess pulmonary function and symptoms in patients with moderate to severe COPD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACLIDINIUM BROMIDE
Condition Name
Clinical Trial Locations for ACLIDINIUM BROMIDE
Trials by Country
Clinical Trial Progress for ACLIDINIUM BROMIDE
Clinical Trial Phase
Clinical Trial Sponsors for ACLIDINIUM BROMIDE
Sponsor Name
